Sotac Pharma.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE0O2D01012
NSEID: SOTAC
BSEID:

INR

123.10

-6.45 (-4.98%)

BSENSE

Dec 31

BSE+NSE Vol: 2400

Click here to access the older version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Smruthi Organic

Parnax Lab

Auro Labs.

Genesis IBRC

Sotac Pharma.

Lactose (India)

Kimia Bioscien.

Tyche Industries

Vaishali Pharma

Krebs Biochem

Achyut Healthcar

Why is Sotac Pharmaceuticals Ltd ?

Weak Long Term Fundamental Strength as the company has not declared results in the last 6 months

Poor long term growth as Net Sales has grown by an annual rate of 11.90% over the last 5 years
Low ability to service debt as the company has a high Debt to EBITDA ratio of 2.56 times

Flat results in Jun 24

Below par performance in long term as well as near term

Along with generating -100.00% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sotac Pharma. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Sotac Pharma.

12.63%

0.28

45.81%

Sensex

9.06%

0.78

11.58%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

11.90%

EBIT Growth (5y)

40.49%

EBIT to Interest (avg)

2.52

Debt to EBITDA (avg)

3.03

Net Debt to Equity (avg)

0.65

Sales to Capital Employed (avg)

1.33

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

16.14%

ROCE (avg)

9.99%

ROE (avg)

10.55%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.44

EV to EBIT

33.41

EV to EBITDA

20.51

EV to Capital Employed

1.88

EV to Sales

1.65

PEG Ratio

0.36

Dividend Yield

0.08%

ROCE (Latest)

5.61%

ROE (Latest)

8.58%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

RSI

Bearish

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Bearish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Loading Valuation Snapshot...

Here's what is working for Sotac Pharma.

Profit After Tax (PAT) - Nine Monthly

At Rs 4.13 cr has Grown at 46.32 %

Year on Year (YoY)

MOJO Watch

Near term PAT trend is very positive

PAT (Rs Cr)

Profit After Tax (PAT) - Nine Monthly

Higher at Rs 4.13 Cr

than preceding 12 month period ended Jun 2024 of Rs 3.47 cr

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

PAT (Rs Cr)